It was 1917 when Felix d’Herelle, at the Institut Pasteur in Paris, first proposed using bacteriophages select or phages)—viruses that infect bacteria—as a therapy for human bacterial infections.

Researchers have developed a method to produce engineered lysins that can be used to selectively kill bacteria of interest while leaving others unharmed. The discovery presents a promising alternative ...

Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, have ...

YONKERS, NY--(Marketwired - Aug 17, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of ...

New method to customise lysins to specifically target unwanted bacteria while leaving others unharmed Lysins are enzymes that help break open the bacteria cells while treating infections, and have ...

Lysins are natural anti-bacterial hydrolytic enzymes that are produced from a bacteriophage, a virus that infects and kills bacteria. Once inside the bacteria, bacteriophages replicate and produce ...

Researchers have developed a strategy to identify new antimicrobial drugs with therapeutic promise from bacterial datasets, providing clues for discovering alternatives to traditional antibiotics. The ...

Scientists in New York have found that a protein called lysin extracted from bacteriophage could lead to life-saving medicine to combat antibiotic-resistant infections. The drugs have reached the ...

Although whole phage continue to generate interest as an alternative to antibiotics, focus is shifting to the use of purified phage components as antibacterial agents. When phages were first ...

NEW YORK--(BUSINESS WIRE)--Bioharmony Therapeutics, Inc. (“Bioharmony”), a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, announced ...

Researchers have developed a strategy to identify new antimicrobial drugs with therapeutic promise from bacterial datasets, providing clues for discovering alternatives to traditional antibiotics.